Navigation Links
Parkinson's Disease Treatment Pipeline is Likely to Meet Many Unmet Needs, says GBI Research
Date:1/12/2016

LONDON, January 12, 2016 /PRNewswire/ --

The treatment pipeline for Parkinson's disease offers a markedly more promising landscape from the current market, says GBI Research.

Analysis from business intelligence provider GBI Research - Frontier Pharma: Parkinson's Disease - Identifying and Commercializing First-in-Class Innovation - states that the current Parkinson's disease treatment market relies on neuromodulators, and although symptoms may be eased, there is not an agent that has demonstrated neuroprotective properties to prevent or at least significantly slow neuronal cell death.

The pipeline for Parkinson's disease, however, is highly active, consisting of 365 programs across all stages of development, and a diverse range of molecular targets. For a complimentary sample of this research, please visit the GBI Research website.

Analyst Angel Wong: "The Parkinson's disease treatment pipeline is characterized by a high level of innovation compared to the central nervous system segment and the industry as a whole, with 43% of all pipeline programs with disclosed molecular targets being first-in-class.

"While neuromodulators remain dominant in the pipeline, there are a number of targets which address different pathogenic mechanisms underlying neurodegeneration in Parkinson's disease. This demonstrates a shift from traditional symptomatic treatments to disease-modifying therapies."

The analyst adds that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson's disease market in the long term.  

GBI Research's report also states that there are 94 first-in-class products available for strategic consolidations, meaning a vast number of investment opportunities are available for licensing or co-development deals in Parkinson's disease.

Wong explains: "There is substantial focus on early-stage collaboration in Parkinson's disease, especially for first-in-class products. This is predominantly driven by growing unmet needs, the current lack of disease-modifying therapies and a desire for risk-sharing.

"Several first-in-class products have demonstrated promising preclinical evidence, and have significant potential to become game-changing products, representing high-reward investments."

About GBI Research 

GBI Research is a leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key healthcare industry influencers to ensure you stay up-to-date with the latest market trends.

For more information, please contact GBI Research on: +44-161-359-5817

For the full range of market-leading analysis on the pharmaceutical industry, visit GBI Research's report store.

Follow GBI Research online for the latest healthcare industry updates:

Facebook | LinkedIn | Twitter


'/>"/>
SOURCE GBI Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
2. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
3. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
4. TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map
5. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
6. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
7. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Investigational New Drug Application Cleared by FDA for OMS824 in Huntingtons Disease
10. Health Diagnostic Laboratory, Inc. Announces Diabetes Prevention & Management Panel for Early Detection and Treatment of Disease
11. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):